PET/CT各代谢参数联合检测对中老年非小细胞肺癌患者预后的评估价值

  目的  探究PET/CT各代谢参数联合检测对中老年非小细胞肺癌（NSCLC）患者预后评估价值。  方法  选择2018年3月~2019年8月来我院就诊的中老年NSCLC患者50例，患者均进行PET/CT检测及随访，记录患者总生存时间（OS）以及无进展生存时间（PFS），并采用Kaplan-Meier法、Log-rank检验以及Cox回归分析法分析PET/CT代谢参数与其预后关系。  结果  50例患者的整体中位OS为28.25月，中位PFS为15.25月，1年、2年、3年的OS分别为80.00%、56.00%、36.00%，1年、2年、3年的PFS分别为60.00%、34.00%、18.00%。PET/CT对T、N、M分期的诊断符合率分别为92.00%、94.00%、98.00%；单因素分析显示，TNM分期、病灶最大直径、手术、最大标准摄取值、代谢肿瘤体积（MTV）、糖酵解总量（TLG）是PFS以及OS的影响因素（P<0.05）；多因素分析显示，MTV、TLG是PFS的独立危险因素，TNM分期、MTV、TLG是OS的独立危险因素。  结论  MTV、TLG是影响NSCLC患者PFS及OS的独立危险因素，PET/CT代谢参数对于评估患者的疾病进展具有一定价值。 

Evaluation value of PET/CT metabolism parameters for prognosis in middle aged and elderly patients with non-small cell lung cancer

  Objective  To explore the evaluation value of PET/CT metabolism parameters for prognosis in middle aged and elderly patients with non-small cell lung cancer (NSCLC).  Methods  Fifty middle aged and elderly patients with NSCLC treated in the hospital were enrolled from March 2018 to August 2019. All patients underwent PET/CT examinations and follow-up. The overall survival (OS) and progression-free survival (PFS) were recorded. The relationship between PET/CT metabolism parameters and prognosis was analyzed by Kaplan-Meier method, Log-rank test and Cox regression analysis.  Results  Overall median OS and median PFS were 28.25 months and 15.25 months of the 50 patients, respectively. The 1-year, 2- year and 3-year OS and PFS were 80.00%, 56.00%, 36.00% and 60.00%, 34.00%, 18.00%, respectively. The diagnostic coincidence rates of PET/CT for T, N and M staging were 92.00%, 94.00% and 98.00%, respectively. Univariate analysis showed that TNM staging, maximum lesion diameter, surgery, SUV_max, MTV and TLG were influencing factors of PFS and OS (P<0.05). Multivariate analysis showed that MTV and TLG were independent risk factors of PFS, while TNM staging, MTV and TLG were independent risk factors of OS.  Conclusion  MTV and TLG are independent risk factors of PFS and OS in patients with NSCLC. PET/CT metabolism parameters have certain evaluation value for disease progression.